Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Pluri Inc.

pluri-biotech.com
Filed: Mar 25, 2026HAIFA, L3CIK: 0001158780Biotechnology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pluri Inc. secured $2.5 million in funding through a private placement of 625,000 common shares and warrants at $4.00 per share, with existing shareholder and director Alexandre Weinstein leading the investment to support operational growth.

Key Takeaways

Private placement raises $2.5 million ($4.00 per share × 625,000 shares) for operational capital

Warrants issued with $4.25 exercise price provide upside potential for investor and future dilution consideration

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 25, 2026
Item1.01
CategoryMaterial Agreement
CIK0001158780
Accession #001-31392
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offeringmaterial agreement

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings